MarylandThe National Cancer Institute’s Kidney/Bladder Cancer Progress
Review Group has released 13 priority recommendations intended to serve as a
national plan to guide research in the two diseases over the next 5 years. The
recommendations cover basic and translational research, cancer control, and
cancer treatment, and range from understanding the biologic mechanisms
underlying the two diseases to developing innovative strategies to eradicate
"The priorities have an important synergy in that
progress in one area will bolster progress in others," the NCI review
group report said. "Supporting priorities in only one or two areas will
not be enough to advance our knowledge and understanding of these cancers. We
must make a commitment to research along the entire continuum."
The review groupco-chaired by Peter Jones, PhD, of the
University of Southern California Cancer Research Center, and Nicholas J.
Vogelzang, MD, of the University of Chicago Cancer Research Centerwas one of
a series of such committees appointed by former NCI director Richard D.
Klausner, MD. NCI has now deferred naming any new program review groups pending
an evaluation of the reports already made.
"The priorities outlined in this report are a blueprint
for progress toward preventing, diagnosing, and treating kidney and bladder
cancers," Dr. Jones and Dr. Vogelzang wrote in the introduction to the
The recommendations cover four general areas: Discovery,
translational research, treatment, and cancer control.
1. Understand the biologic mechanisms underlying the risk
factors for kidney and bladder cancer phenotypes. "Novel prevention and
treatment strategies may result from improved understanding of such
mechanisms," the report said.